Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
New York, USA, June 25, 2026 (GLOBE NEWSWIRE) -- IgA Nephropathy Clinical Trial Space Intensifies with 25+ Companies in Active Development | DelveInsight The IgA nephropathy clinical trial analysis...
-
New York, USA, June 23, 2026 (GLOBE NEWSWIRE) -- Acute Kidney Injury Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...
-
June 15, 2026 Announcement no. 13 Grant of Warrants Copenhagen, Denmark, June 15, 2026, (GLOBE NEWSWIRE) – The Board of...
-
15 juni 2026 Meddelelse nr. 13 Tildeling af Warrants København, Danmark, den 15. juni 2026 (GLOBE NEWSWIRE) – Bestyrelsen...
-
June 9, 2026Announcement no. 12 BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback COPENHAGEN, DENMARK, June 9, 2026 – BioPorto A/S (“BioPorto”...
-
9. juni, 2026Meddelelse nr. 12 BioPorto planlægger amerikansk voksenvalideringsstudie efter feedback fra den amerikanske Food and Drug Administration (FDA) KØBENHAVN, DANMARK, 9. juni, 2026 –...
-
May 21, 2026Announcement no. 11 BioPorto announces Interim Result for the First Quarter of 2026 Copenhagen,...
-
21. maj 2026Meddelelse nr. 11 BioPorto annoncerer det midlertidige resultat for første kvartal af 2026 ...
-
May 12, 2026 News release BioPorto A/S to host an investor webcast on the results for the first quarter of 2026 COPENHAGEN, DENMARK, May 12, 2026 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or...
-
12. maj 2026 Pressemeddelelse BioPorto A/S afholder webcast for investorer om resultatet for første kvartal 2026 København, Danmark, 12. maj 2026 (GLOBE NEWSWIRE) – BioPorto...